{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
ADC Therapeutics SA
ADC Therapeutics SA Hits New 52-Week High of $4.67
ADC Therapeutics SA has achieved a new 52-week high of USD 4.67, marking a significant milestone for the microcap company in the Pharmaceuticals & Biotechnology sector. Over the past year, it has gained 21.7%, showcasing effective management despite being loss-making and navigating a challenging market landscape.
ADC Therapeutics SA Hits New 52-Week High of USD 4.31
ADC Therapeutics SA achieved a new 52-week high of USD 4.31 on October 3, 2025, significantly up from its low of USD 1.05. With a market cap of USD 405 million, the company has a strong return on equity of 84.56% and a unique financial structure reflected in its debt-to-equity ratio.
ADC Therapeutics SA Hits New 52-Week High of USD 4.07
ADC Therapeutics SA has achieved a new 52-week high, reflecting a significant increase from its previous low. The company, with a market capitalization of USD 405 million, operates in the Pharmaceuticals & Biotechnology industry and demonstrates strong return on equity, despite its loss-making status and unique financial metrics.
Is ADC Therapeutics SA technically bullish or bearish?
As of September 8, 2025, ADC Therapeutics SA has a mildly bullish trend, supported by bullish MACD and Bollinger Bands, but faces caution from some bearish indicators, while it has outperformed the S&P 500 recently despite significant long-term underperformance.
Is ADC Therapeutics SA overvalued or undervalued?
As of August 3, 2021, ADC Therapeutics SA is considered risky and overvalued due to significant financial distress, reflected in its negative key ratios and poor long-term performance, despite a strong year-to-date stock return.
Is ADC Therapeutics SA overvalued or undervalued?
As of August 3, 2021, ADC Therapeutics SA is considered overvalued and risky due to negative financial ratios, a P/E ratio of -2.1005, and a return of only 1.13% over the past year, significantly underperforming the S&P 500's 10.26% return.
Is ADC Therapeutics SA technically bullish or bearish?
As of June 10, 2025, the technical trend is mildly bullish, supported by the weekly MACD and KST, despite mixed signals from daily moving averages and Bollinger Bands.
Who are in the management team of ADC Therapeutics SA?
As of March 2022, the management team of ADC Therapeutics SA includes Chairman Ron Squarer, CEO Chris Martin, Vice Chairman and CFO Michael Forer, and Board Members Dr. Peter Corr and Dr. Peter Hug. This team is responsible for the company's strategic direction and operations.
What does ADC Therapeutics SA do?
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology company specializing in antibody drug conjugates for cancer treatment. As of March 2025, it reported net sales of $23 million and a net loss of $39 million, with a market cap of $343.74 million.
How big is ADC Therapeutics SA?
As of Jun 18, ADC Therapeutics SA has a market capitalization of 343.74 million and reported net sales of 75.81 million, with a net profit of -149.84 million over the last four quarters. The balance sheet shows shareholder's funds of -202.64 million and total assets of 321.98 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
